Advanced soft-tissue sarcoma and treatment options: Critical appraisal of trabectedin
AuthorDesar, Ingrid M. E.
Kaal, Suzanne E. J.
Jones, Robin Lewis
Graaf, W. T. A. van der
SourceCancer Management and Research
Google Scholar check
MetadataShow full item record
Soft-tissue sarcomas (STS) are a heterogeneous group of rare solid tumors of mesenchymal origin. This paper reviews the current status of systemic treatment in advanced and metastatic soft tissue sarcomas, with an emphasis on trabectedin. Trabectedin is a unique type of chemotherapeutic agent with multiple potential mechanisms of action. We discuss the putative mechanisms, as well as the toxicity and administration schedules of trabectedin, followed by its efficacy in first-line systemic therapy and beyond first-line systemic therapy. © 2016 Desar et al.